Subdivision 1. Health care practitioner duties. (a) Prior to a patient's enrollment in the registry program, a health care practitioner shall:
(1) determine, in the health care practitioner's medical judgment, whether a patient suffers from a qualifying medical condition, and, if so determined, provide the patient with a certification of that diagnosis;
(2) advise patients, registered designated caregivers, and parents, legal guardians, or spouses who are acting as caregivers of the existence of any nonprofit patient support groups or organizations;
(3) provide explanatory information from the commissioner to patients with qualifying medical conditions, including disclosure to all patients about the experimental nature of therapeutic use of medical cannabis; the possible risks, benefits, and side effects of the proposed treatment; the application and other materials from the commissioner; and provide patients with the Tennessen warning as required by section 13.04, subdivision 2; and
(4) agree to continue treatment of the patient's qualifying medical condition and report medical findings to the commissioner.
(b) Upon notification from the commissioner of the patient's enrollment in the registry program, the health care practitioner shall:
(1) participate in the patient registry reporting system under the guidance and supervision of the commissioner;
(2) report health records of the patient throughout the ongoing treatment of the patient to the commissioner in a manner determined by the commissioner and in accordance with subdivision 2;
(3) determine, on a yearly basis, if the patient continues to suffer from a qualifying medical condition and, if so, issue the patient a new certification of that diagnosis; and
(4) otherwise comply with all requirements developed by the commissioner.
(c) A health care practitioner may conduct a patient assessment to issue a recertification as required under paragraph (b), clause (3), via telehealth, as defined in section 62A.673, subdivision 2.
(d) Nothing in this section requires a health care practitioner to participate in the registry program.
Subd. 2. Data. Data collected on patients by a health care practitioner and reported to the patient registry are health records under section 144.291, and are private data on individuals under section 13.02, but may be used or reported in an aggregated, nonidentifiable form as part of a scientific, peer-reviewed publication of research conducted under section 152.25 or in the creation of summary data, as defined in section 13.02, subdivision 19.
Subd. 3. Advertising restrictions. (a) A health care practitioner shall not publish or cause to be published any advertisement that:
(1) contains false or misleading statements about medical cannabis or about the medical cannabis registry program;
(2) uses colloquial terms to refer to medical cannabis, such as pot, weed, or grass;
(3) states or implies the health care practitioner is endorsed by the Department of Health or by the medical cannabis registry program;
(4) includes images of cannabis in its plant or leaf form or of cannabis-smoking paraphernalia; or
(5) contains medical symbols that could reasonably be confused with symbols of established medical associations or groups.
(b) A health care practitioner found by the commissioner to have violated this subdivision is prohibited from certifying that patients have a qualifying medical condition for purposes of patient participation in the registry program. The commissioner's decision that a health care practitioner has violated this subdivision is a final decision of the commissioner and is not subject to the contested case procedures in chapter 14.
2014 c 311 s 8; 1Sp2017 c 6 art 10 s 126; 1Sp2019 c 9 art 11 s 92; 2021 c 30 art 3 s 36; 1Sp2021 c 7 art 6 s 28
Structure Minnesota Statutes
Chapter 152 — Drugs; Controlled Substances
Section 152.02 — Schedules Of Controlled Substances; Administration Of Chapter.
Section 152.021 — Controlled Substance Crime In The First Degree.
Section 152.022 — Controlled Substance Crime In The Second Degree.
Section 152.023 — Controlled Substance Crime In The Third Degree.
Section 152.024 — Controlled Substance Crime In The Fourth Degree.
Section 152.025 — Controlled Substance Crime In The Fifth Degree.
Section 152.026 — Mandatory Sentences.
Section 152.0261 — Importing Controlled Substances Across State Borders.
Section 152.0262 — Possession Of Substances With Intent To Manufacture Methamphetamine Crime.
Section 152.027 — Other Controlled Substance Offenses.
Section 152.0271 — Notice Of Drug Convictions; Driver's License Revocation.
Section 152.0273 — Synthetic Drug Sales; Mandatory Restitution.
Section 152.028 — Permissive Inference Of Knowing Possession.
Section 152.092 — Possession Of Drug Paraphernalia Prohibited.
Section 152.093 — Manufacture Or Delivery Of Drug Paraphernalia Prohibited.
Section 152.094 — Delivery Of Drug Paraphernalia To A Minor Prohibited.
Section 152.095 — Advertisement Of Drug Paraphernalia Prohibited.
Section 152.096 — Conspiracies Prohibited.
Section 152.097 — Simulated Controlled Substances.
Section 152.0972 — Precursors Of Controlled Substances.
Section 152.0973 — Report Of Transaction.
Section 152.0974 — Exceptions.
Section 152.10 — Sales, Persons Eligible.
Section 152.101 — Manufacturers, Records.
Section 152.11 — Prescriptions.
Section 152.12 — Health Care Providers May Prescribe.
Section 152.125 — Intractable Pain.
Section 152.126 — Prescription Monitoring Program.
Section 152.13 — Duties Of State Board Of Pharmacy.
Section 152.135 — Restrictions On Sales, Marketing, And Possession Of Ephedrine.
Section 152.136 — Anhydrous Ammonia; Prohibited Conduct; Criminal Penalties; Civil Liability.
Section 152.137 — Methamphetamine-related Crimes Involving Children And Vulnerable Adults.
Section 152.152 — Stayed Sentence Limited.
Section 152.18 — Discharge And Dismissal.
Section 152.20 — Penalties Under Other Laws.
Section 152.205 — Local Regulations.
Section 152.21 — Thc Therapeutic Research Act.
Section 152.24 — Federally Approved Clinical Trials.
Section 152.25 — Commissioner Duties.
Section 152.261 — Rules; Adverse Incidents.
Section 152.27 — Patient Registry Program Established.
Section 152.28 — Health Care Practitioner Duties.
Section 152.29 — Manufacturer Of Medical Cannabis Duties.
Section 152.30 — Patient Duties.
Section 152.31 — Data Practices.
Section 152.32 — Protections For Registry Program Participation.
Section 152.34 — Health Care Facilities.
Section 152.35 — Fees; Deposit Of Revenue.
Section 152.36 — Impact Assessment Of Medical Cannabis Therapeutic Research.